Home > Cardiology > AHA 2020 > CVD Risk Reduction > Safety and efficacy of inclisiran for hypercholesterolemia

Safety and efficacy of inclisiran for hypercholesterolemia

Presented By
Prof. R. Scott Wright, Mayo Clinic, USA
Conference
AHA 2020
Trial
Phase 3, ORION

Three placebo-controlled phase 3 trials have evaluated the efficacy and safety of inclisiran. Inclisiran lowered low-density lipoprotein (LDL) cholesterol similarly across all ages with an acceptable safety profile [1]. The efficacy and safety profile of inclisiran was generally similar in both sexes [2].

Prof. R. Scott Wright (Mayo Clinic, USA) presented the results of 2 pooled analyses evaluating the efficacy and safety of inclisiran according to age and sex, respectively. Both analyses included data from three phase 3 placebo-controlled trials:

    1. ORION-9 in patients with heterozygous familial hypercholesterolaemia (HeFH);
    2. ORION-10 in patients with atherosclerotic cardiovascular disease (ASCVD); and
    3. ORION-11 in patients with ASCVD or ASCVD risk equivalents.

In the first analysis, a total of 3,660 patients were categorised according to age: <65 yea...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on